Whalesbook
Amrutanjan Health Care Ltd announced its audited results for the fiscal year ended March 31, 2026, reporting revenue of ₹502.55 crore and profit after tax of ₹57.92 crore.
The Board of Directors met on May 8, 2026, to approve the financial figures.
Dividend and Governance
The board recommended a final dividend of ₹2.90 per equity share for FY26, subject to shareholder approval at the upcoming Annual General Meeting (AGM). The dividend is expected to be paid within 30 days of the AGM.
Key governance changes were approved, including the appointment of Mr. Ramaswami Krishnan as a Non-Executive Independent Director, effective May 8, 2026. Mr. Muralidharan Swayambunathan was also re-appointed for a second five-year term, starting June 29, 2026.
Furthermore, the company approved a revised Employee Stock Option Plan, known as 'ESOP 2'.
Company Context and Competition
Amrutanjan Health Care is an established Indian company recognized for its pain balm and its presence in the broader FMCG and healthcare sectors. For the previous fiscal year, FY 2024-25, the company reported revenue of approximately ₹470 crore and profit after tax of ₹52 crore.
Operating in the Indian FMCG and healthcare market, Amrutanjan competes with larger players such as Dabur India Ltd and Marico Ltd. Dabur India reported revenues around ₹11,637 crore in FY24, while Marico Ltd posted revenues of about ₹10,676 crore in the same period. Amrutanjan's FY26 revenue of ₹502.55 crore positions it as a smaller, more niche player focused on specific wellness categories.
Shareholder Returns and Oversight
The dividend recommendation offers a direct return to shareholders, signaling confidence in sustained profitability. The addition of experienced independent directors is expected to strengthen the company's governance framework and oversight. The revised ESOP scheme aims to align employee interests with company performance.
No specific risks were detailed in the filing.
Looking Ahead
Investors will watch for shareholder approval of the director appointments at the AGM, the timely payout of the dividend, and any management commentary on future growth strategies or segment performance. Details on the revised 'ESOP 2' scheme and its potential impact on the equity structure will also be of interest.